Project ALS
One application of our longevity and rejuvenation platform is advancing target discovery and drug design for late-onset diseases such as Amyotrophic Lateral Sclerosis. We integrate timeline-based epigenetic signatures with ALS-specific mutations and biochemical pathway data, then embed these patterns into advanced AI/ML models. Combined with our deep expertise in target structure analysis, we can identify potent, druggable targets that can be modulated precisely and safely, without neurotoxic side effects.
Our unique contribution
We support our academic partner working with mouse models and post-mortem tissues by providing naturally derived composite probes that help validate therapeutic targets and clarify their underlying biochemical pathways.
How our software supports
Our molecular dynamics-based software is capable of generating picomolar activity solutions based on highly accurate 3D structural models and deep understanding of active sites.
Our artificial intelligence engine integrates large-scale ALS and control patient data—combining structural genomics, conserved and collapse-inducing mutations, evolutionary sequence alignments, and time-resolved epigenetic patterns—to uncover meaningful biological signals and accelerate target discovery.
Collaboration and progress
At Foldyne ALS, we are committed to advancing innovation in the life sciences. Project ALS is an example of how we are applying our expertise to address complex challenges and contribute to the development of new treatments. Contact us using the contact form to discuss how you can contribute to this important and potentially life-saving research.